Martha Morrell - 15 May 2026 Form 4 Insider Report for NeuroPace Inc (NPCE)

Reporting relationship: CHIEF MEDICAL OFFICER
Issuer ticker: NPCE
Reported as of: 15 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2026, 16:27:18 UTC
Prior SEC filing: 25 Mar 2026
Next SEC filing: 28 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Leah Akin, Attorney-in-Fact

Key filing fact

Martha Morrell filed Form 4 for NeuroPace Inc (NPCE) on 19 May 2026.

Key facts

This page summarizes Martha Morrell's Form 4 filing for NeuroPace Inc (NPCE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 May 2026, 16:27.

Change

Previous filing in this sequence was filed on 25 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001855616 Primary reporting owner

Morrell Martha

Relationship: CHIEF MEDICAL OFFICER
Address: C/O NEUROPACE INC., 455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Signature: /s/ Leah Akin, Attorney-in-Fact
Signature date: 19 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NPCE transaction

Common Stock

Award

Transaction value
Shares: +5,460
Change %: +12%
Price: $0.000000^*
Shares after: 52,743
Date: 15 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NPCE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +14,550
Change %
Price: $0.000000^*
Shares after: 14,550
Date: 15 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,550
Exercise price: $15.36
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on May 15, 2027 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter.

Footnote F2

25% of the shares subject to the option vest on May 15, 2027. The remaining shares subject to the option vest in thirty six (36) equal consecutive monthly installments thereafter.